Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2024

Key Points

• The study aims to investigate the reporting frequencies of hematological and thrombotic adverse events associated with immune checkpoint inhibitor therapy.
• Analyzed reporting data from the FDA Adverse Event Reporting System (FAERS) between 2014 and 2024.
• Examined combination regimens for stronger reporting signals of adverse events.
• Assessed the timelines of reporting and associated mortality rates.
• Identified notable frequencies of hematological and thrombotic adverse events linked to immune checkpoint inhibitors.
• Combination therapies showed significant signals for certain adverse events.
• Early reporting and high mortality proportions emphasized the need for heightened clinical vigilance.